Compare Moderna, Inc. (MRNA) vs Zillow Group Inc Class C (Z) Price & Performance

Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.

While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.

Zillow Group (Z) trades at $29.17, up 6.93% in the past 24 hours, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growing from $2.2B in 2024 to $2.6B in 2025, and net income turning positive at $23M after a $112M loss the prior year. Recent earnings show two consecutive beats, with Q2 2026 EPS of $0.52 exceeding expectations of $0.4459. Analyst consensus remains divided with a $60.33 price target representing significant upside potential from current levels.

The outlook for Zillow appears cautiously optimistic with improving profitability and strategic AI integration, though the stock faces headwinds from high mortgage rates and housing market volatility. The company's transition to an integrated transaction platform shows promise, but execution risks remain amid competitive pressures and regulatory scrutiny. With a P/E ratio of 126.83 indicating premium valuation, investors should monitor housing market trends and the company's ability to sustain recent earnings momentum.